Actavis sells its outsourcing biz to TPG

Actavis ($ACT) is selling its in-house R&D outsourcing company to private equity giant TPG, which has plans for more bolt-on acquisitions. The segment, Aptalis Pharmaceutical Technologies, handles R&D and manufacturing for biopharma clients, specializing in formulation and customized drug release. TPG, a part owner of Quintiles ($Q), now plans to use Aptalis as a platform for growth, signing deals and buying additional companies to raise its profile on the market. More

Suggested Articles

The platform uses wearables to continuously collect clinical data from study participants and applies machine learning to analyze the data.

Analytica Laser has a novel system which the company touts as the industry's first dynamic tool to predict real-world health outcomes.

Genae's CEO says the transaction reflects recent focus on digital health and data-driven services.